ArticleJournal of cellular and molecular medicine2026
METTL3/YTHDF1-Driven SURF6 Promotes Prostate Cancer Stemness via CDK4.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prostate cancer (PCa) remains a major health challenge globally, necessitating the identification of novel therapeutic targets to improve patient outcomes. This study investigates the role of the SURF6 gene in PCa, focusing on its expression patterns, molecular mechanisms, and biological behaviours in vitro and in vivo. We employed a combination of bioinformatics analysis, gene expression profiling, Western blotting, and functional assays, including cell proliferation, migration, invasion, and stemness assays, to evaluate the impact of SURF6 modulation in PCa cell lines. Our findings demonstrate that SURF6 is significantly upregulated in PCa tissues compared to adjacent normal tissues, with elevated expression correlating with poor prognosis and advanced clinical stages. Functional assays revealed that silencing SURF6 inhibited PCa cell proliferation, migration, and invasion, while overexpression of SURF6 enhanced these malignant characteristics. Notably, we identified that SURF6 regulates CDK4 expression, which plays a pivotal role in cell cycle progression and maintenance of stem-like properties, as evidenced by the modulation of cancer stem cell markers such as CD44 and Nanog. Furthermore, we elucidated that METTL3 and YTHDF1 regulate SURF6 expression through m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.